Literature DB >> 21570850

Surgical management of an Irish cohort of BRCA-mutation carriers.

Paul A Carroll1, Carmel Nolan, Roisin Clarke, Michael Farrell, Noreen Gleeson, Terry Boyle, Barbara Dunne, Peter A Daly, M John Kennedy, Elizabeth M Connolly.   

Abstract

Little information is available regarding the management of BRCA-related breast cancer in Ireland. A cancer genetics programme was initiated in 1992 at our institution to provide counselling and expert management for those with cancers resulting from inherited predisposition. We examined a cohort of BRCA mutation-carriers treated at a single institution over 16 years. A total of 107 women from 57 families were found to be carriers of mutations in BRCA1/2. Bilateral salpingo-oophorectomy was the most common prophylactic surgery performed. Overall survival between BRCA-related and sporadic breast cancer was equivalent. This is the first publication on surgical management of BRCA-mutation carriers in Ireland. It is imperative that those considered likely to harbour a mutation are referred early to a dedicated clinic so that appropriate counselling, testing and subsequent management to reduce the risk of dying from cancer can be undertaken.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21570850     DOI: 10.1016/j.breast.2011.04.005

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  2 in total

1.  Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study.

Authors:  E M Walsh; M P Farrell; C Nolan; F Gallagher; R Clarke; J A McCaffrey; M J Kennedy; M Barry; M R Kell; D J Gallagher
Journal:  Ir J Med Sci       Date:  2015-02-12       Impact factor: 1.568

Review 2.  Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis.

Authors:  Alexandra J van den Broek; Marjanka K Schmidt; Laura J van 't Veer; Rob A E M Tollenaar; Flora E van Leeuwen
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.